Gayer Charles K, an insider at BioCryst Pharmaceuticals Inc (BCRX), purchased 902,583 shares at a price of $5.04 per share on December 21, 2025. The total value of the transaction amounted to $4.55 million. Following this purchase, Gayer holds a total of 902,583 shares in the company.
BioCryst Pharmaceuticals operates in the biotechnology sector and is headquartered in Durham, North Carolina. The company employs 580 full-time staff and specializes in developing first-in-class oral small-molecule and protein therapeutics aimed at treating challenging diseases. Its marketed products include ORLADEYO, used for the prevention of hereditary angioedema attacks, and RAPIVAB, an injection for treating acute uncomplicated influenza.
The company has a market capitalization of $1.4 billion and reported an EPS of -0.17 for the trailing twelve months. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of $0.08 and revenue of $158.6 million, followed by another report on August 3, 2026, with an EPS estimate of $0.09 and revenue of $173.2 million.
Insider transactions, such as this purchase, must be reported to the SEC, providing transparency into executive stock activity. While such buying can indicate confidence in the company's future, it is important for investors to consider these transactions alongside other factors rather than in isolation.